| Data set | Procedure | What's in this data set | Panel | Sex | Age (weeks) | Year |
|---|---|---|---|---|---|---|
|
|
body weight
with influenza A (H5N1) virus |
Influenza A (H5N1) virus (several doses) vs. baseline. | inbred (23) | f | 6-9wks | 2011 |
|
|
health assessment
with influenza A (H5N1) virus |
Survival rate, influenza A (H5N1) virus (several doses). Strain H5N1 susceptibility score. | inbred (23) | f | 6-9wks | 2011 |
|
|
health assessment
with Plasmodium berghei |
Susceptibility, Plasmodium berghei (malaria). Parasitemia in blood and distribution in brain, spleen, lungs, liver. | inbred (31) | both | 8-12wks | 2010 |
|
|
body weight
with Theiler's murine encephalomyelitis virus |
Body weight | CC (5) | both | 4wks | 2017 |
|
|
health assessment
with Theiler's murine encephalomyelitis virus |
Clinical health assessment scores, TMEV infection. | CC (5) | both | 4wks | 2017 |
|
|
RNA expression profiling
with Theiler's murine encephalomyelitis virus |
TMEV transcript abundance. | CC (5) | both | 4wks | 2017 |
|
|
open field test
with Theiler's murine encephalomyelitis virus |
Locomotor activity, TMEV infection. | CC (5) | both | 4wks | 2017 |
|
|
gait analysis
with Theiler's murine encephalomyelitis virus |
DigiGait analysis and footprint analysis, TMEV infection. | CC (5) | both | 4wks | 2017 |
|
|
rotarod
with Theiler's murine encephalomyelitis virus |
Latency to fall from accelerating rotarod, TMEV infection. | CC (5) | both | 4wks | 2017 |
|
|
health assessment
with Staphylococcus aureus |
Survival rate, Staphylococcus aureus. | inbred (13) | f | 8wks | 2012 |
|
|
hormone quantification
with Staphylococcus aureus |
Interleukin 6 levels (serum) after infection with Staphylococcus aureus. Kidney and peritoneal fluid. | inbred (13) | f | 8wks | 2012 |
|
|
in vitro assay
with Staphylococcus aureus |
Bacterial load after infection with Staphylococcus aureus. Kidney and peritoneal fluid. In vitro assay. | inbred (13) | f | 8wks | 2012 |
|
|
in vitro assay
with Bacillus anthracis lethal toxin |
Bacillus anthracis lethal toxin (anthrax) susceptibility. | inbred (50) | f | 6-8wks* | 1998 |
|
|
body weight
with influenza A (H1N1) virus |
Body weight | CC pre w/par (163) | f | 8-16wks | 2012 |
|
|
health assessment
with influenza A (H1N1) virus |
Clinical health assessment score and strain susceptibility index 4 days after infection with influenza A (H1N1) virus. | CC pre w/par (163) | f | 8-16wks | 2012 |
|
|
in vitro assay
with influenza A (H1N1) virus |
Viral replication log titer 4 days after infection with influenza A (H1N1) virus. In vitro. | CC pre w/par (163) | f | 8-16wks | 2012 |
|
|
histopathology
with influenza A (H1N1) virus |
Lungs and airway 4 days after infection with influenza A (H1N1) virus. | CC pre w/par (163) | f | 8-16wks | 2012 |
|
|
body weight
with West Nile virus |
Body weight | CC RIX (5) | m | 8-10wks | 2015 |
|
|
health assessment
with West Nile virus |
Clinical score. | CC RIX (5) | m | 8-10wks | 2015 |
|
|
immune cell quantification
with West Nile virus |
T cell populations in brain and spleen. | CC RIX (5) | m | 8-10wks | 2015 |
|
|
RNA expression profiling
with West Nile virus |
Viral load and expression of Ifnb1 and Ifit1 in brain, kidney and spleen. | CC RIX (5) | m | 8-10wks | 2015 |
|
|
colony observation
with SARS-CoV |
Body weight loss and mortality. | CC RIX (117) | f | 8-10wks | 2021 |
|
|
in vitro assay
with SARS-CoV |
Lung viral load (log10). | CC RIX (117) | f | 8-10wks | 2021 |
|
|
in vitro assay
with Candida albicans |
Susceptibility to infection with Candida albicans. | inbred (36) | f | 8-12wks | 2011 |
|
|
health assessment
with Plasmodium chabaudi |
Survival score and susceptibility, Plasmodium chabaudi. | inbred (25) | both | 8-10wks | 2012 |
|
|
microscopy
with Plasmodium chabaudi |
Percent of Plasmodium chabaudi-infected erythrocytes in blood. | inbred (25) | both | 8-10wks | 2012 |
|
|
in vitro assay
with Neisseria musculi |
Bacterial load after inoculation with Neisseria musculi. Oral cavity. | inbred w/CC8 (8) | both | 8-16wks | 2018 |
|
|
study archive | Spleen, liver murine cytomegalovirus study. | QTL population | both | 8-12wks | 2009 |
|
|
body weight
with influenza A (H1N1) virus |
Influenza A (H1N1) virus vs. baseline. Several timepoints. | inbred (9) | both | 10-12wks | 2009 |
|
|
health assessment
with influenza A (H1N1) virus |
Strain susceptibility score, influenza A (H1N1) virus. | inbred (9) | both | 10-12wks | 2009 |
|
|
body weight
with influenza A (H1N1) virus |
Influenza A (H1N1) virus vs. baseline. Several timepoints.. | BXD w/par (56) | f | 9-18wks | 2012 |
|
|
health assessment
with influenza A (H1N1) virus |
Survival rate, susceptibility, influenza A (H1N1) virus. | BXD w/par (56) | f | 9-18wks | 2012 |
|
|
body weight
with influenza A (H3N2) virus |
Influenza A (H3N2) virus (several doses) vs. baseline. Several timepoints. | inbred w/CC8 (8) | both | 7-13wks | 2013 |
|
|
health assessment
with influenza A (H3N2) virus |
Survival rate, susceptibility, influenza A (H3N2) virus (several doses). | inbred w/CC8 (8) | both | 7-13wks | 2013 |
|
|
body weight
with influenza A (H3N2) virus |
Influenza A (H3N2) virus vs. controls. Several timepoints. | inbred w/CC8 (8) | f | 8-12wks | 2016 |
|
|
in vitro assay
with influenza A (H3N2) virus |
Viral load in lungs after infection with influenza A (H3N2) virus. | inbred w/CC8 (8) | f | 8-12wks | 2016 |
|
|
body weight
with influenza A (H3N2) virus |
Influenza A (H3N2) virus vs. controls. Several timepoints. | inbred w/CC8 (8) | f | 8-12wks | 2016 |